JGC
KDNY

J. Goldman & Co’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

J. Goldman & Co’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,000
Closed -$295K – 368
2019
Q4 		$295K Buy
+50,000
New +$272K 0.02% 232

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

J. Goldman & Co's KDNY Position: Q1 2020 in Review

J. Goldman & Co sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2020, closing a stake of 50,000 shares — an estimated $295K sold.

J. Goldman & Co first reported a position in KDNY in Q4 2019 and held it in 1 quarter. The position peaked at $295K in Q4 2019. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2020.

  • J. Goldman & Co reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • J. Goldman & Co sold 50,000 Chinook Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $295K.
  • J. Goldman & Co first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • J. Goldman & Co's Chinook Therapeutics, Inc. Common Stock position peaked at $295K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2020.

Based on J. Goldman & Co's 13F filing for Q1 2020, filed 15 May 2020.